An Observational Study of Cetuximab with Platinum-based Chemotherapy for First-line Treatment in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Trial Profile

An Observational Study of Cetuximab with Platinum-based Chemotherapy for First-line Treatment in Patients with Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms ENCORE
  • Most Recent Events

    • 13 Oct 2017 New trial record
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top